Search Results

You are looking at 1 - 10 of 83 items for :

  • polycystic ovary syndrome x
Clear All
Open access

Katica Bajuk Studen and Marija Pfeifer

Introduction Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age, with a prevalence 5–16% under different diagnostic criteria and across several ethnic groups, with exact pathogenesis still unclear ( 1 , 2 , 3

Open access

Yao Chen and Shu-ying Fang

Introduction Polycystic ovary syndrome (PCOS) is a heterogeneous and complex disorder of reproductive aged women, which usually causes reproduction and metabolism failure ( 1 , 2 ). It often presents as hyperandrogenism, hyperinsulinemia

Open access

Shilpa Lingaiah, Laure Morin-Papunen, Terhi Piltonen, Inger Sundström-Poromaa, Elisabet Stener-Victorin and Juha S Tapanainen

Introduction Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with an estimated prevalence of 6–15%, depending on the criteria used for diagnosis ( 1 ). It is a heterogeneous disorder with

Open access

Angela Köninger, Antonella Iannaccone, Ensar Hajder, Mirjam Frank, Boerge Schmidt, Ekkehard Schleussner, Rainer Kimmig, Alexandra Gellhaus and Hans Dieplinger

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) . Human Reproduction 2004 19 41 – 47 . ( ) 4 Fauser BC Tarlatzis BC Rebar RW Legro RS Balen

Open access

Sanna Mustaniemi, Marja Vääräsmäki, Johan G Eriksson, Mika Gissler, Hannele Laivuori, Hilkka Ijäs, Aini Bloigu, Eero Kajantie and Laure Morin-Papunen

Introduction Gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS) are the most common endocrine disorders in women of reproductive age. The prevalence of GDM varies from 9% to 25% and the prevalence of PCOS varies from 5

Open access

Krzysztof C Lewandowski, Justyna Płusajska, Wojciech Horzelski, Ewa Bieniek and Andrzej Lewiński

presented in Table 2 . Table 2 Percentile distribution of insulin resistance indices in a group of 478 women with polycystic ovary syndrome. Percentiles HOMA (95% CI) IRI (Belfiore) (95% CI) QUICKI (95% CI) McAuley (95% CI

Open access

Raymond J Rodgers, Jodie C Avery, Vivienne M Moore, Michael J Davies, Ricardo Azziz, Elisabet Stener-Victorin, Lisa J Moran, Sarah A Robertson, Nigel K Stepto, Robert J Norman and Helena J Teede

Introduction Following the recent release of international guidelines for management of polycystic ovary syndrome (PCOS) ( 1 ) endorsed by 38 international organisations in 71 countries, the research, clinical and consumer PCOS communities

Open access

Sebastião Freitas de Medeiros, Cinthia Marenza Ormond, Matheus Antônio Souto de Medeiros, Nayara de Souza Santos, Camila Regis Banhara and Márcia Marly Winck Yamamoto

Introduction After standardization of the diagnostic criteria for polycystic ovary syndrome (PCOS) the hyperandrogenemic phenotype has been found in nearly 80% of patients ( 1 , 2 ). These hyperandrogenemic patients may have their androgen

Open access

Sebastião Freitas de Medeiros, Márcia Marly Winck Yamamoto, Matheus Antônio Souto de Medeiros, Bruna Barcelo Barbosa, José Maria Soares Junior and Edmund Chada Baracat

Introduction Polycystic ovary syndrome (PCOS) has a prevalence ranging from 5 to 20% in women of reproductive age, depending on the population and criteria used for making a definitive diagnosis ( 1 , 2 ). The use of ultrasound may increase

Open access

Angela Köninger, Philippos Edimiris, Laura Koch, Antje Enekwe, Claudia Lamina, Sabine Kasimir-Bauer, Rainer Kimmig and Hans Dieplinger

Introduction The polycystic ovary syndrome (PCOS) is one of the most frequent endocrine disorders, found in up to 8% of women of reproductive age (1) . According to the Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group, the diagnosis is